{"entity":{"id":"nct06689163","kind":"trial","name":"A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone","aka":[],"tldr":"A phase 1/2 trial of Prednisone in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone is a phase 1/2 interventional study registered as NCT06689163 by Jiangsu HengRui Medicine Co., Ltd., with 66 participants planned, started 2024-12-11 and due to reach its primary completion in 2025-11-30. Interventions recorded: HRS-1167 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06689163","url":"https://clinicaltrials.gov/study/NCT06689163"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["prednisone"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06689163","phase":"1/2","setting":"An Open, Multicenter Phase Ib/II Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":66,"outcomes":[]},"route":"/trials/nct06689163/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}